|
|
||||||||
Lasco A, Cucinotta D, Gigante A, Denuzzo G, Pedulla M, Trifiletti A, Frisina N. No changes of peripheral insulin resistance in polycystic ovary syndrome after long-term reduction of endogenous androgens with leuprolide. Eur J Endocrinol 1995;133:718–22. ISSN 0804–4643
The aim of this study was to investigate the relationship between plasma insulin levels, peripheral insulin sensitivity and androgen secretion in ten patients with polycystic ovary syndrome and in six obese women as compared with six normal-weight control subjects. During a euglycemic–hyperinsulinemic clamp no significant change of testosterone, androstenedione or dehydroepiandrosterone sulfate plasma levels was observed in the two groups of patients or in the control subjects; insulin sensitivity was clearly reduced and was similar in polycystic ovary patients and in obese women, in spite of the different plasma androgen levels. A long-term (5 months) androgen suppression with the gonadotropin-releasing hormone agonist leuprolide was not able to improve significantly the insulin sensitivity. These results demonstrate that the short-term hyperinsulinemia achieved with the clamp technique does not affect androgen secretion and that insulin resistance, measured with the same technique, is not influenced by long-term suppression of plasma androgen levels in polycystic ovary syndrome.
A Lasco, Via Faustina e Tertullo 19, 98100 Messina, Italy
This article has been cited by other articles:
![]() |
A Corbould Chronic testosterone treatment induces selective insulin resistance in subcutaneous adipocytes of women J. Endocrinol., March 1, 2007; 192(3): 585 - 594. [Abstract] [Full Text] [PDF] |
||||
![]() |
E. Volpi, S. A. Lieberman, D. M. Ferrer, C. R. Gilkison, B. B. Rasmussen, M. Nagamani, and R. J. Urban The Relationships Between Testosterone, Body Composition, and Insulin Resistance: A lesson from a case of extreme hyperandrogenism Diabetes Care, February 1, 2005; 28(2): 429 - 432. [Full Text] [PDF] |
||||
![]() |
D. Cibula Is insulin resistance an essential component of PCOS?: The influence of confounding factors Hum. Reprod., April 1, 2004; 19(4): 757 - 759. [Abstract] [Full Text] [PDF] |
||||
![]() |
V.L. Armstrong, M.I. Wiggam, C.N. Ennis, B. Sheridan, A.I. Traub, A.B. Atkinson, and P.M. Bell Insulin action and insulin secretion in polycystic ovary syndrome treated with ethinyl oestradiol/cyproterone acetate QJM, January 1, 2001; 94(1): 31 - 37. [Abstract] [Full Text] [PDF] |
||||
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH | TABLE OF CONTENTS |